OX40/CD134 - Predilute - 6.0 ml

Product Description

The OX40 receptor, also known as CD134, is a tumour necrosis superfamily receptor (TNSFR4) that is recognised as a costimulatory receptor for T cells. OX40 is predominantly expressed on activated CD4 T cells. OX40 has been shown to be essential for the regulation, differentiation, and survival of conventional CD4 and CD8 T cells. Multiple studies have demonstrated that activation of the OX40 receptor via ligand or agonist (antibody) binding enhances T cell-mediated anti-tumour immunity.

Based on its critical co-stimulatory role in T-cell based anti-tumour immunity, OX40 has been identified as a promising therapeutic target in late-stage cancers. Additional studies have suggested the utility of combination therapies involving OX40 activation in conjunction with CTLA-4 or PD-1 suppression: enabling the proliferation of T-cells while removing the suppressive action of “immune checkpoint inhibitors”.

Specifications:

• Intended Use: IVD
• Format: Predilute
• Volume: 6.0 ml
• Species Reactivity: Human; others not tested
• Source: Rabbit Monoclonal
• Clone: EPR23001-88
• Isotype: IgG
• Antigen: OX40/CD134
• Localisation: Tonsil
• Positive Control: Membrane